Patents by Inventor Patrick Eugene BURNETT

Patrick Eugene BURNETT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES
    Publication number: 20250352526
    Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, tinea versicolor, pityriasis versicolor, tinea circinata, tinea pedis, tinea unguium, tinea manus, tinea cruris, tinea corporis, tinea faciei, tinea capitis, and/or tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
    Type: Application
    Filed: June 12, 2025
    Publication date: November 20, 2025
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David Reuben BERK, Patrick Eugene BURNETT, Saori KATO, David W. OSBORNE
  • Topical roflumilast formulation having antifungal properties
    Patent number: 12329751
    Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: June 17, 2025
    Assignee: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David Reuben Berk, Patrick Eugene Burnett, Saori Kato, David W. Osborne
  • TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES
    Publication number: 20230321057
    Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, tinea versicolor, pityriasis versicolor, tinea circinata, tinea pedis, tinea unguium, tinea manus, tinea cruris, tinea corporis, tinea faciei, tinea capitis, and/or tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
    Type: Application
    Filed: June 15, 2023
    Publication date: October 12, 2023
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David Reuben BERK, Patrick Eugene BURNETT, Saori KATO, David W. OSBORNE
  • Topical roflumilast formulation having antifungal properties
    Patent number: 11707454
    Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: July 25, 2023
    Assignee: Arcutis Biotherapeutics, Inc.
    Inventors: David Reuben Berk, Patrick Eugene Burnett, Saori Kato, David W. Osborne
  • TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES
    Publication number: 20220175743
    Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.
    Type: Application
    Filed: December 3, 2021
    Publication date: June 9, 2022
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventors: David Reuben BERK, Patrick Eugene BURNETT, Saori KATO, David W. OSBORNE